Seaport Completes Spin-Off from PureTech and Raises $100 Million in Series A Financing
WilmerHale represented Seaport Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing novel neuropsychiatric medicines, in connection with its
spin-off from PureTech Health and its $100 million oversubscribed
Series A financing round. The transactions enable Seaport to progress its pipeline of novel neuropsychiatric medicines based on its Glyph™ Technology Platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce hepatotoxicity and other side effects to advance active drugs that were previously held back by those limitations. The financing was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and PureTech. The WilmerHale team representing Seaport consisted of
Stuart Falber,
Sarah Hogan,
Will Myer,
Pooja Sudarshan,
Adam Camiel,
Ben Goldfein,
Matthew O’Malley,
Scott Kilgore,
Julie Hogan Rodgers and
Kim Wethly.
